Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055243 | 0.89 | DPP4 (0.49) | DPP4SLC1A1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL11221173 | 0.89 | DPP4 (0.49) | DPP4SLC1A1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL27899116 | 0.89 | DPP4 (0.49) | DPP4SLC1A1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL24187349 | 0.83 | DPP4 (0.43) | DPP4SLC1A1AAK1SLC7A5SLC1A3 | |
| SCHEMBL31618904 | 0.83 | DPP4 (0.43) | DPP4SLC1A1AAK1SLC7A5SLC1A3 | |
| Cadaverine Tartrate SCHEMBL28961395 | 0.82 | DPP4 (0.39) | DPP4SLC1A1AAK1SLC7A5SLC1A3 | |
| Cadaverine Tartrate SCHEMBL28961238 | 0.82 | DPP4 (0.39) | DPP4SLC1A1AAK1SLC7A5SLC1A3 | |
| SCHEMBL27670609 | 0.80 | CTSS (0.47) | SLC1A1AAK1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL28761485 | 0.76 | AAK1 (0.41) | DPP4AAK1 | |
| SCHEMBL27694464 | 0.74 | SLC1A1 (0.48) | SLC1A1SLC7A5SLC1A3SLC1A2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101871-B2 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885SLC1A1 635/4885AAK1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.